These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

734 related articles for article (PubMed ID: 10668858)

  • 1. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.
    Dresser GK; Spence JD; Bailey DG
    Clin Pharmacokinet; 2000 Jan; 38(1):41-57. PubMed ID: 10668858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs.
    Zhou S; Yung Chan S; Cher Goh B; Chan E; Duan W; Huang M; McLeod HL
    Clin Pharmacokinet; 2005; 44(3):279-304. PubMed ID: 15762770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs.
    Ohno Y; Hisaka A; Suzuki H
    Clin Pharmacokinet; 2007; 46(8):681-96. PubMed ID: 17655375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects.
    Mueck W; Kubitza D; Becka M
    Br J Clin Pharmacol; 2013 Sep; 76(3):455-66. PubMed ID: 23305158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions.
    Decker CJ; Laitinen LM; Bridson GW; Raybuck SA; Tung RD; Chaturvedi PR
    J Pharm Sci; 1998 Jul; 87(7):803-7. PubMed ID: 9649346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.
    Damkier P; Hansen LL; Brosen K
    Br J Clin Pharmacol; 1999 Dec; 48(6):829-38. PubMed ID: 10594487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug interactions with cisapride: clinical implications.
    Michalets EL; Williams CR
    Clin Pharmacokinet; 2000 Jul; 39(1):49-75. PubMed ID: 10926350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Grapefruit juice-drug interactions.
    Bailey DG; Malcolm J; Arnold O; Spence JD
    Br J Clin Pharmacol; 1998 Aug; 46(2):101-10. PubMed ID: 9723817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance.
    Neuvonen PJ; Niemi M; Backman JT
    Clin Pharmacol Ther; 2006 Dec; 80(6):565-81. PubMed ID: 17178259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYP3A4 drug interactions: correlation of 10 in vitro probe substrates.
    Kenworthy KE; Bloomer JC; Clarke SE; Houston JB
    Br J Clin Pharmacol; 1999 Nov; 48(5):716-27. PubMed ID: 10594474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.
    Venkatakrishnan K; von Moltke LL; Greenblatt DJ
    Clin Pharmacokinet; 2000 Feb; 38(2):111-80. PubMed ID: 10709776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components.
    Eagling VA; Profit L; Back DJ
    Br J Clin Pharmacol; 1999 Oct; 48(4):543-52. PubMed ID: 10583025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring.
    Zhou SF; Xue CC; Yu XQ; Li C; Wang G
    Ther Drug Monit; 2007 Dec; 29(6):687-710. PubMed ID: 18043468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors.
    Williams D; Feely J
    Clin Pharmacokinet; 2002; 41(5):343-70. PubMed ID: 12036392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative distinctions of active site molecular recognition by P-glycoprotein and cytochrome P450 3A4.
    Wang E; Lew K; Barecki M; Casciano CN; Clement RP; Johnson WW
    Chem Res Toxicol; 2001 Dec; 14(12):1596-603. PubMed ID: 11743742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir.
    Mikus G; Schöwel V; Drzewinska M; Rengelshausen J; Ding R; Riedel KD; Burhenne J; Weiss J; Thomsen T; Haefeli WE
    Clin Pharmacol Ther; 2006 Aug; 80(2):126-35. PubMed ID: 16890574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 6',7'-Dihydroxybergamottin in grapefruit juice and Seville orange juice: effects on cyclosporine disposition, enterocyte CYP3A4, and P-glycoprotein.
    Edwards DJ; Fitzsimmons ME; Schuetz EG; Yasuda K; Ducharme MP; Warbasse LH; Woster PM; Schuetz JD; Watkins P
    Clin Pharmacol Ther; 1999 Mar; 65(3):237-44. PubMed ID: 10096255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nortriptyline E-10-hydroxylation in vitro is mediated by human CYP2D6 (high affinity) and CYP3A4 (low affinity): implications for interactions with enzyme-inducing drugs.
    Venkatakrishnan K; von Moltke LL; Greenblatt DJ
    J Clin Pharmacol; 1999 Jun; 39(6):567-77. PubMed ID: 10354960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Involvement of multiple human cytochromes P450 in the liver microsomal metabolism of astemizole and a comparison with terfenadine.
    Matsumoto S; Yamazoe Y
    Br J Clin Pharmacol; 2001 Feb; 51(2):133-42. PubMed ID: 11259984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience.
    van Heeswijk RP; Veldkamp A; Mulder JW; Meenhorst PL; Lange JM; Beijnen JH; Hoetelmans RM
    Antivir Ther; 2001 Dec; 6(4):201-29. PubMed ID: 11878403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.